Johnson & Johnson (JNJ) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with JNJ
Recent news

Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
JNJ

PFE vs. JNJ: Which Stock Is the Better Value Option?
PFE vs. JNJ: Which Stock Is the Better Value Option?
JNJ

Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Share Its Reliability
Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Share Its Reliability
JNJ

Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
JNJ
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 38.15
- MACD 12/26/9
- -2.89
- EMA 9 of MACD
- -1.30
- MACD histogram
- -1.58
- SMA 50
- $265.22
- Price below SMA 50
- EMA 50
- $262.75
- Price below EMA 50
- SMA 200
- $242.65
- Price above SMA 200
- EMA 200
- $241.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 12 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.95 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
JNJ

PFE vs. JNJ: Which Stock Is the Better Value Option?
PFE vs. JNJ: Which Stock Is the Better Value Option?
JNJ

Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Share Its Reliability
Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Share Its Reliability
JNJ

Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
JNJ

Johnson & Johnson or Procter & Gamble: If I Could Only Own 1 Dividend King for 20 Years, This Is It
Johnson & Johnson or Procter & Gamble: If I Could Only Own 1 Dividend King for 20 Years, This Is It
JNJ

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
JNJ

Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
JNJ

Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.
Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.
JNJ

J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
JNJ

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ
News tone: automated (AI) classification of the article's content, not a price prediction.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Every day, our more than 130,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joaquin Duato | CEO & Chairman | 1963 |
| Mr. Joseph James Wolk CPA | Executive VP & CFO | 1967 |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine and R&D | 1958 |
| Mr. Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 1970 |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | 1973 |
| Mr. James Swanson | Executive VP & Chief Information Officer | 1966 |
| Mr. Ryan Koors | Vice President of Investor Relations | — |
| Mr. Dirk Brinckman | Chief Compliance Officer | — |
| Ms. Elizabeth Forminard J.D. | Executive VP & Chief Legal Officer | 1971 |
| Ms. Kristen Blair Mulholland | Executive VP & Chief HR Officer | 1967 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 38.15
- MACD 12/26/9
- -2.89
- EMA 9 of MACD
- -1.30
- MACD histogram
- -1.58
- SMA 50
- $265.22
- Price below SMA 50
- EMA 50
- $262.75
- Price below EMA 50
- SMA 200
- $242.65
- Price above SMA 200
- EMA 200
- $241.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $263.00
- Average
- $291.33
- High
- $320.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.6 | -4.3 | +8.2 | |||||||||
| 2022 | +0.4 | -3.7 | +8.1 | +1.3 | +0.5 | -0.1 | -2.8 | -7.2 | -1.2 | +6.6 | +2.8 | -1.2 |
| 2023 | -8.3 | -7.1 | +1.6 | +4.4 | -5.2 | +7.1 | +2.6 | -4.3 | -2.9 | -4.4 | +4.0 | -1.0 |
| 2024 | -0.7 | +1.9 | -2.4 | -8.4 | -3.0 | -1.1 | +7.8 | +3.2 | -3.1 | -1.3 | -3.2 | -6.6 |
| 2025 | +5.6 | +8.7 | -0.9 | +2.0 | +0.5 | -1.7 | +5.7 | +5.9 | +4.1 | +1.5 | +11.1 | +0.8 |
| 2026 | +9.6 | +7.7 | -1.7 | -5.8 | -0.8 | +13.6 | +0.9 | +4.5 | -2.4 | -0.8 |
Corporate actions
Upcoming
No upcoming corporate actions for JNJ



